Clinical trials: Prostatic Adenocarcinoma
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer (Adenocarcinoma), Vitamin D on Tumor Response and Inflammatory Markers
Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression
This study is testing whether fixing vitamin D deficiency in Black/West African men with prostate cancer can strengthen their immune system, improve quality of life, and even slow cancer progression compared to those who remain…
- Trial name
- iCCaRE (NCT07598032)
- Testing
- vitamin D 25(OH)D
- Where
- Nigeria
- Volunteers
- 200 people
- Sponsor
- University of Ilorin Teaching Hospital
Prostate Cancer, Sexual Dysfunction
High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer
RATIONALE: Highly focused ultrasound energy may be able to kill tumor cells by heating the tumor without affecting the surrounding tissue.
- Conditions
- Prostate Cancer, Sexual Dysfunction, Urinary Incontinence
- Trial name
- NCT00561314
- Testing
- questionnaire administration, biopsy, high-intensity focused ultrasound ablation
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- University College London Hospitals
Prostate Cancer (Adenocarcinoma)
Robot-Assisted Radical Prostatectomy: the HOOD Technique Versus Standard Anterior Reconstruction
This prospective, non-randomized cohort study included consecutive patients undergoing robotic-assisted laparoscopic radical prostatectomy (RARP) between January 2024 and January 2026 following ethics committee approval.
- Trial name
- NCT07417475
- Testing
- Prostatectomy with anterior-posterior renconstruciton, Prostatectomy with HOOD techinque
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Araz Musaev
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent).
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03371719
- Testing
- Apalutamide, External Beam Radiation Therapy
- Where
- 360 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- NRG Oncology
Male Breast Carcinoma, Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the…
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT02206334
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- NRG Oncology
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Trial name
- Solar-Recur (NCT06235099)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 31 sites in United States
- Volunteers
- 235 people
- Sponsor
- Curium US LLC
Prostate Cancer, Prostate Adenocarcinoma
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial.
- Trial name
- CAPTAIN (NCT05027477)
- Testing
- Radical Prostatectomy, TULSA Procedure
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 201 people
- Sponsor
- Profound Medical Inc.
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Adenocarcinoma, Stage I Prostate Cancer
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer
The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men's ability to work and to describe and compare changes in work ability (as measured through…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- PCW (NCT03963739)
- Testing
- Interview, Questionnaire Administration
- Where
- 326 sites in United States, Guam
- Volunteers
- 255 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Pain, Prostate Cancer
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain.
- Conditions
- Pain, Prostate Cancer, Quality of Life
- Trial name
- NCT00003232
- Testing
- clodronate disodium, mitoxantrone hydrochloride, prednisone
- Where
- 21 sites in Canada
- Volunteers
- 227 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Adenocarcinoma
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer.
- Trial name
- NCT04288687
- Testing
- Niraparib Pill
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT02023463
- Testing
- Enzalutamide, Goserelin acetate, Leuprolide acetate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.